血清抗存活素抗体水平在肺部良恶性肿瘤中的对照研究  

Comparison of serum anti-survivin antibody levels between benign and malignant lung tumor

作　　者：张卫红[1] 侯静朴[1] 王国臣[1] 李作生[1] 

机构地区：[1]河北联合大学附属医院胸心外科,唐山063000

出　　处：《中国综合临床》2011年第5期509-511,共3页Clinical Medicine of China

摘　　要：目的比较血清抗存活素抗体水平在肺部良、恶性肿瘤之间表达的差异，为将抗存活素抗体作为非小细胞肺癌筛查指标提供依据。方法采用ELISA法检测健康体检者60名（对照组）、肺良性病变60例（肺良性病变组）、非小细胞肺癌60例（非小细胞肺癌组）血清中抗存活素抗体的含量。结果抗存活素抗体在对照组[11．7％（7／60）]中几乎不表达，在肺良性病变组中表达率为[20．0％（12／60）]，两者之间表达差异无统计学意义。在非小细胞肺癌组的外周血中阳性表达率68．3％（41／60），与肺良性病变组之间表达差异有统计学意义（X^2=38．352，P〈0．01），与对照组比较差异亦有统计学意义（X^2=41．798，P〈0．01）。结论抗存活素抗体在健康人群及肺良性病变患者中不表达，而在非小细胞肺癌中高表达，可为非小细胞肺癌诊断提供重要依据，并可作为非小细胞肺癌的筛查指标。Objective To compare the serum anti-survivin antibody levels between benign and malignant lung tumor,thus to provide evidence for using anti-survivin antibody as an indicator in non-small cell lung cancer. Methods ELISA was used to measure the level of anti-survivin antibody in healthy population （ control group, n = 60） , benign lung tumor patients （ benign lung tumor group, n = 60 ） and non-small cell lung cancer patients （non-small cell lung cancer group, n = 60）. Results The anti-surviving antibody did not express 11.7% （7/60） in the control group and almost no expression 20. 0% （12/60） in the benign lung tumor group, with no significant difference between the two groups （ P 〉 0.05 ）. In the non-small cell lung cancer group, the anti-survivin antibody expressed in 41 patients, which was significantly higher than those in the benign lung tumor group （X^2 = 38. 352, P 〈 0. 01 ）. Conclusion Anti-survivin antibody does not express in the healthy population and the benign lung tumor patients, whereas shows high expression in non-small cell lung cancer. This finding indicates that anti-survivin antibody can provide important evidence for non-small cell lung cancer diagnosis, and can be used as an indicator for non-small lung cancer screening.

关 键 词：抗存活素抗体 非小细胞肺癌 存活素 鳞癌 腺癌 肺良性病变 

分 类 号：R734.2[医药卫生—肿瘤]